Search
Guardant Health Inc
GHAdd to Watchlist
153.740USD
+4.520+3.03%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
20.22BMarket Cap
LossP/E TTM
More Details of Guardant Health Inc Company
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Guardant Health Inc Info
Ticker SymbolGH
Company nameGuardant Health Inc
IPO dateOct 04, 2018
CEOTalasaz (Amirali)
Number of employees1999
Security typeOrdinary Share
Fiscal year-endOct 04
Address3100 Hanover Street
CityPALO ALTO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94304
Phone18556988887
Websitehttps://guardanthealth.com/
Ticker SymbolGH
IPO dateOct 04, 2018
CEOTalasaz (Amirali)
Company Executives of Guardant Health Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.44M
+2.60%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
83.94K
+4.80%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
72.00K
+7.81%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
38.47K
-21.04%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
36.44K
+1.33%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
28.52K
+14.74%
Ms. Myrtle Stephens Potter
Ms. Myrtle Stephens Potter
Independent Director
Independent Director
20.97K
+12.62%
Ms. Meghan V. Joyce
Ms. Meghan V. Joyce
Independent Director
Independent Director
15.39K
+27.32%
Mr. Musa Tariq
Mr. Musa Tariq
Independent Director
Independent Director
11.05K
+21.60%
Dr. Amirali Talasaz, Ph.D.
Dr. Amirali Talasaz, Ph.D.
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Helmy A. Eltoukhy, Ph.D.
Dr. Helmy A. Eltoukhy, Ph.D.
Chairperson of the Board, Co-Chief Executive Officer
Chairperson of the Board, Co-Chief Executive Officer
2.44M
+2.60%
Dr. Darya Chudova
Dr. Darya Chudova
Chief Technology Officer
Chief Technology Officer
83.94K
+4.80%
Dr. Craig Eagle, M.D.
Dr. Craig Eagle, M.D.
Chief Medical Officer
Chief Medical Officer
72.00K
+7.81%
Mr. Kumud Kalia
Mr. Kumud Kalia
Chief Information Officer
Chief Information Officer
38.47K
-21.04%
Mr. John Gomes Saia
Mr. John Gomes Saia
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
36.44K
+1.33%
Ms. Vijaya V. Gadde
Ms. Vijaya V. Gadde
Independent Director
Independent Director
28.52K
+14.74%
FAQs
Who are the top five shareholders of Guardant Health Inc?
The top five shareholders of Guardant Health Inc are: Dr. Helmy A. Eltoukhy, Ph.D.
How many institutions hold shares of Guardant Health Inc (GH)?
As of 2026Q1, 894 institutions hold shares of Guardant Health Inc, with a combined market value of approximately 134.76M, accounting for 101.63% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -4828187.00.
What is the biggest source of revenue for Guardant Health Inc?
In 2026Q1, the Oncology business generated the highest revenue for Guardant Health Inc, amounting to 683.60M and accounting for 69.61% of total revenue.
